NeoGenomics, Inc. Stock News

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will debut its PanTracer Family and unveil the Paletrra platform at ASCO 2025, advancing precision oncology diagnostics.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.

Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no rally can continue forever, so investors may measure momentum across different timeframes.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.